Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Yale University National Alliance for Research on Schizophrenia and Depression |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00563797 |
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients with depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake inhibitor (SSRI).
Condition | Intervention | Phase |
---|---|---|
Alcohol Dependence Depression |
Drug: Mecamylamine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence |
Estimated Enrollment: | 30 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Depression with co-morbid alcohol dependence is very prevalent and it is very costly to treat. The co occurrence of the two disorders leads to greater severity and worse long-term outcome, including suicide. Although a number of treatment strategies have been implemented for depressed patients with alcohol dependence the controversy concerning best treatment options for those patients persists. The clinical relationship between depression and alcohol dependence suggests some common mechanism underlying both disorders. It has been hypothesized that medications that block presynaptic nAChR may be effective in the treatment of alcoholism and depression. Mecamylamine (Inversine ®) is a noncompetitive, high affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Mecamylamine has never been investigated as an effective adjunct treatment for dually diagnosed patients with depression and alcohol dependence. Methods: Thirty participants with a current diagnosis of depression and alcohol dependence will be recruited for this 12-week treatment study. Fifteen participants will be randomized to mecamylamine and fifteen to placebo.
Participants will be included in the study if: they meet current DSM-IV criteria for Major Depression and Alcohol Dependence and have been on a stable SSRI dose for 2 weeks. All participants will come weekly to take their medications and complete weekly assessments. Weekly assessments will consist of questioners that will assess depressive symptoms and alcohol consumption over the entire treatment period. Significance: This study is the first to evaluate the efficacy of mecamylamine as an augmenting agent for treatment of depression and alcohol dependence.
Ages Eligible for Study: | 21 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Elizabeth Ralevski, Ph.D. | 203-932-5711 ext 4282 | elizabeth.ralevski@yale.edu |
United States, Connecticut | |
VA Connecticut Healthcare System | Recruiting |
West Haven, Connecticut, United States, 06516 | |
Contact: Elizabeth Ralevski, Ph.D. 203-932-5711 ext 4282 elizabeth.ralevski@yale.edu | |
Principal Investigator: Elizabeth Ralevski, Ph.D. |
Principal Investigator: | Elizabeth Ralevski, Ph.D. | Yale University |
Responsible Party: | Yale University ( Elizabeth Ralevski ) |
Study ID Numbers: | HSS # ER0002 |
Study First Received: | November 21, 2007 |
Last Updated: | June 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00563797 History of Changes |
Health Authority: | United States: Institutional Review Board |
treatment alcohol dependence depression mecamylamine |
Neurotransmitter Agents Depression Cholinergic Antagonists Disorders of Environmental Origin Mecamylamine Cardiovascular Agents Cholinergic Agents Depressive Disorder Antihypertensive Agents |
Behavioral Symptoms Mental Disorders Alcoholism Substance-Related Disorders Mood Disorders Alcohol-Related Disorders Peripheral Nervous System Agents Ethanol |
Ganglionic Blockers Neurotransmitter Agents Depression Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Nicotinic Antagonists Physiological Effects of Drugs Disorders of Environmental Origin Mecamylamine Cardiovascular Agents Cholinergic Agents Depressive Disorder |
Antihypertensive Agents Pharmacologic Actions Behavioral Symptoms Autonomic Agents Mental Disorders Therapeutic Uses Alcoholism Substance-Related Disorders Mood Disorders Alcohol-Related Disorders Peripheral Nervous System Agents |